Top Banner
Jemma Gatliff Future Health Summit Dublin, May 2016
10

Jemma Gatliff, Keregen

Apr 11, 2017

Download

Healthcare

Investnet
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Jemma Gatliff, Keregen

   

Jemma Gatliff Future Health Summit

Dublin, May 2016

Page 2: Jemma Gatliff, Keregen

   •  Overview of Keregen Therapeutics •  Our Journey •  Accelerator programs •  Aligning with academia

Page 3: Jemma Gatliff, Keregen

àUK-based early stage drug discovery and àdevelopment company

àUCL School of Pharmacy Start-up/Future Spin-out

àFounded in 2015

àOperating out of UCL/Stevenage Bioscience Catalyst

Keregen Therapeutics:

Page 4: Jemma Gatliff, Keregen

GEOFF WELLS, Chair of SAB

Management Team

JEMMA GATLIFF, CEO NICK GEORGAKOPOULOS, CSO

Industry Advisors

ILAN ZIPKIN Takeda Ventures Inc. SAM FAZELI Bloomberg ANDY SANDHAM Bicycle Therapeutics/ 14M Genomics KEITH POWELL Canbex Therapeutics ROD PORTER Rod Porter Consulting

Scientific Partners

ALBENA DINKOVA-KOSTOVA University of Dundee BIRGITT SCHUELE Parkinson’s Institute, CA JEFF JOHNSON University of Wisconsin KENNETH SMITH Institute of Neurology, UCL TILO KUNATH University of Edinburgh

Page 5: Jemma Gatliff, Keregen

àFirst-in-class non-covalent small àmolecule Nrf2 activators

àDisease modifying therapeutic àintervention in Parkinson’s

àSafety profile – better or equal to àmarketed symptomatic therapy

àOral once daily route of àadministration

Target Product Profile:

Page 6: Jemma Gatliff, Keregen

Developing precision medicines for patients with

high unmet clinical need

PATIENT FOCUS •  More than five million

people worldwide have Parkinson’s Disease

•  Long-term progressive illness

•  No disease-modifying treatments

MULTIDISCIPLINARY UNIT •  Structure-based drug

design to proof-of-concept biological validation

R&D DRIVERS •  Targets with genetic

evidence are more successful in drug discovery

Page 7: Jemma Gatliff, Keregen

   •  Overview of Keregen Therapeutics •  Our Journey •  Accelerator programs •  Aligning with academia

Page 8: Jemma Gatliff, Keregen

The journey so far…

2012/13:  Nick  begins  PhD  with  Geoff.  Jemma  meets  Nick    

2014:  Enter  OneStart  

Feb  –  May  15:  Mentoring  from  Ilan  Zipkin  and  others  from  OneStart  

May  15:  Winners  of  OneStart  £100k  prize  

Oct  16  Full-­‐Sme  Keregen  

Jan  16  –    Early  for  market  à  Falls  outside  typical  TTO  model  à  UCL/SBC  incubator  

March-­‐April  16:  4  new  FTEs  

Dec  16  –  Keregen  Incorporated  

May  16:  Move  to  SBC  

Page 9: Jemma Gatliff, Keregen

Accelerator Programs

BUILD A NETWORK •  Advisors and champions

are essential

•  Get advice from experienced people

•  It takes many people to

build a company e.g. finance, legal, scientists, HR

LEARN THE LINGO •  Equip yourself with

business terminology •  Understand the market

opportunity

•  Where does your product fit in?

PITCH PERFECT •  Develop your business

plan

•  1 min, 3 min, 5 min, 20 min pitches

Page 10: Jemma Gatliff, Keregen

Aligning with academia early on

WORK SPACE •  Universities have start-

up space e.g. UCL & Cambridge @ SBC

•  Access to equipment

•  Existing infrastructure

RECRUITING GROUND •  Stay in the loop with

academic research

•  Highly skilled personnel on your door step

MAXIMISE •  Non-dilutive funding

opportunities

•  Collaborative projects: continued pipeline